ADXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Advaxis's change in receivables for the quarter that ended in Mar. 2023 was $0.23 Mil. It means Advaxis's Accounts Receivable declined by $0.23 Mil from Oct. 2022 to Mar. 2023 .
Advaxis's change in receivables for the fiscal year that ended in Oct. 2022 was $0.00 Mil. It means Advaxis's Accounts Receivable stayed the same from Oct. 2021 to Oct. 2022 .
Advaxis's Accounts Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Advaxis's Days Sales Outstanding for the three months ended in Mar. 2023 was 91.25.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Advaxis's liquidation value for the three months ended in Mar. 2023 was $5.52 Mil.
The historical data trend for Advaxis's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advaxis (OTCPK:ADXS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Advaxis's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.004 | / | 0.004 | * | 91 |
= | 91.25 |
2. In Ben Graham's calculation of liquidation value, Advaxis's accounts receivable are only considered to be worth 75% of book value:
Advaxis's liquidation value for the quarter that ended in Mar. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 16.839 | - | 11.32 | + | 0.75 * 0.004 | + | 0.5 * 0 |
= | 5.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Advaxis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Roy Golan | officer: Chief Financial Officer | 24 GOLDA MEIR ST., HOLON L3 5840425 |
Yuval Cabilly | director | C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348 |
Pini Orbach | director | C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802 |
Bridget A Martell | director | C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
Israel Biotech Fund Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Israel Biotech Fund Gp Partners Ii, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Murray A Goldberg | director | 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Vered Bisker-leib | director | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Israel Biotech Fund I, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Israel Biotech Fund Gp Partners, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Yair Chaim Schindel | 10 percent owner | YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110 |
I.b.f. Management Ltd. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Igor Gitelman | officer: Chief Accounting Officer | 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-08-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By Stock market mentor Stock market mentor • 01-12-2023
By GuruFocusNews GuruFocusNews • 05-26-2022
By Marketwired • 08-10-2023
By GuruFocusNews GuruFocusNews • 03-17-2022
By sperokesalga sperokesalga • 06-05-2023
By GuruFocusNews GuruFocusNews • 04-08-2022
By Stock market mentor Stock market mentor • 01-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.